These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22190063)

  • 1. Predicting clopidogrel response using DNA samples linked to an electronic health record.
    Delaney JT; Ramirez AH; Bowton E; Pulley JM; Basford MA; Schildcrout JS; Shi Y; Zink R; Oetjens M; Xu H; Cleator JH; Jahangir E; Ritchie MD; Masys DR; Roden DM; Crawford DC; Denny JC
    Clin Pharmacol Ther; 2012 Feb; 91(2):257-63. PubMed ID: 22190063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
    Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
    Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
    Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
    Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
    Mega JL; Simon T; Collet JP; Anderson JL; Antman EM; Bliden K; Cannon CP; Danchin N; Giusti B; Gurbel P; Horne BD; Hulot JS; Kastrati A; Montalescot G; Neumann FJ; Shen L; Sibbing D; Steg PG; Trenk D; Wiviott SD; Sabatine MS
    JAMA; 2010 Oct; 304(16):1821-30. PubMed ID: 20978260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
    Verschuren JJ; Boden H; Wessels JA; van der Hoeven BL; Trompet S; Heijmans BT; Putter H; Guchelaar HJ; Schalij MJ; Jukema JW
    Int J Cardiol; 2013 Sep; 167(6):2882-8. PubMed ID: 22940005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
    Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
    Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
    Carlquist JF; Knight S; Horne BD; Huntinghouse JA; Rollo JS; Muhlestein JB; May H; Anderson JL
    Thromb Haemost; 2013 Apr; 109(4):744-54. PubMed ID: 23364775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
    Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
    Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population.
    Chen DY; Wang CY; Wen MS; Lee TH; Chu Y; Hsieh MJ; Chang SH; Lee CH; Wang JL; Chen CC; Lu LS; Lee MT; Yeh SJ; Lin FC; Hsieh IC
    PLoS One; 2012; 7(6):e39178. PubMed ID: 22723959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 and clopidogrel response: more than validation in the real world.
    Shuldiner AR
    Clin Pharmacol Ther; 2012 Feb; 91(2):170-1. PubMed ID: 22261685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study.
    Joo HJ; Ahn SG; Park JH; Park JY; Hong SJ; Kim SY; Choi W; Gwon H; Lim YH; Kim W; Kang WC; Cho YH; Kim YH; Yoon J; Shin W; Hong MK; Garg S; Jang Y; Lim DS
    Sci Rep; 2018 Jan; 8(1):1229. PubMed ID: 29352151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
    Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.